pharmaceutical investing Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
